论文部分内容阅读
目的观察舒血宁联合依达拉奉治疗急性脑梗死的疗效。方法将100例脑梗死患者随机分为治疗组和对照组,每组50例,治疗组联合使用舒血宁和依达拉奉,对照组单用舒血宁,两组均治疗1个疗程(14d)后评定疗效,观察两组患者病情的改善情况。结果治疗组总有效率为88%,高于对照组的74%,差异有统计学意义(P<0.05)。两组在治疗过程中均未发现明显不良反应。结论舒血宁联合依达拉奉治疗急性脑梗死疗效显著。
Objective To observe the efficacy of Shuxuening combined with edaravone in the treatment of acute cerebral infarction. Methods 100 patients with cerebral infarction were randomly divided into treatment group and control group, with 50 cases in each group. Shuxuening and edaravone were used in the treatment group, Shuxuening alone in the control group, and one course of treatment was in both groups 14d) after the assessment of efficacy, two groups of patients to observe the improvement of the condition. Results The total effective rate of the treatment group was 88%, which was higher than that of the control group (74%), the difference was statistically significant (P <0.05). No significant adverse reactions were found in both groups during the course of treatment. Conclusion Shuxuening combined edaravone treatment of acute cerebral infarction significant effect.